REGISTER
Hemorrhagic Transformation in Acute Ischemic Stroke Reperfusion
IVT and EVT have substantially improved recanalization in AIS, yet hemorrhagic transformation (HT) remains a key complication, driven by blood-brain barrier disruption and neurovascular unit injury. Risk factors include stroke severity, BP variability, stress hyperglycemia, fibrinogen depletion, leukoaraiosis, and abnormal DWI volume. In TASTE-2, adjunctive edaravone dexborneol during EVT significantly improved 90-day functional independence, supporting reperfusion plus neuroprotection.

Over the past two decades, treatment for acute ischemic stroke (AIS) has undergone revolutionary advances. From intravenous thrombolysis (IVT) to endovascular thrombectomy (EVT), the continuous evolution of reperfusion strategies has substantially improved recanalization rates in patients with large-vessel occlusive stroke [1]. Yet anatomic recanalization of the vessel does not equate to functional independence for the patient. Hemorrhagic transformation (HT), one of the most common complications of reperfusion therapy, remains an enduring challenge in clinical stroke management [2,3].

From a pathophysiologic standpoint, HT is closely tied to blood-brain barrier (BBB) disruption and damage to the neurovascular unit — suggesting that cerebral cytoprotection strategies may be central to reducing HT risk and improving reperfusion outcomes [2,3]. Based on his series of studies in reperfusion therapy, Prof. Yongwei Zhang of the First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital) offers an in-depth analysis of the core issues in HT management.

Expert Profile: Prof. Yongwei Zhang

Prof. Yongwei Zhang, Chief Physician, First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital)

  • l Deputy Director, Cerebrovascular Disease Center; Deputy Director, Clinical Research Ward, First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital).
  • l Serves as Deputy Secretary-General, China Stroke Specialty Alliance; Standing Committee Member and Youth Standing Director, Severe Cerebrovascular Disease Branch, Chinese Stroke Association; Member, Neurocritical Care Collaboration Group, Chinese Medical Association Neurology Branch; Vice Group Leader, Cerebral Artery Stenosis and Occlusion Group, Neurologic Intervention Branch, Chinese Medical Doctor Association; Committee Member, Neurocritical Care Group, Neurologist Branch, Chinese Medical Doctor Association; Standing Committee Member, Severe Brain Injury Committee, China Association for Promotion of Human Health Science and Technology; Standing Committee Member, Neural Injury and Repair Committee, Chinese Research Hospital Association; Committee Member, Stroke Prevention and Control Expert Committee, Chinese Preventive Medicine Association; Committee Member, Stroke Specialty Branch, Shanghai Medical Association; Committee Member, Neurologic Intervention Committee, Shanghai Medical Doctor Association; Youth Committee Member and Member, Cerebrovascular Intervention Group, PLA Neurology Committee.
  • l Recipient of 7 science and technology awards, including Shanghai Science and Technology Progress First Prize and PLA Medical Achievement First Prize. A core member of the Oriental Cerebrovascular Research Consortium (OCEAN Consortium), coordinating the conduct of DIRECT-MT and a series of related clinical RCTs. Author of 97 publications, including representative works in the New England Journal of Medicine and The Lancet. Co-author of 7 monographs; editor-in-chief of Acute Ischemic Stroke Interventional Therapy; contributor to 5 expert consensuses or guidelines on cerebrovascular disease.

Hemorrhagic Transformation: An Inevitable Complication of Reperfusion Therapy

Hemorrhagic transformation refers to intracranial hemorrhage identified on follow-up CT/MRI that was not present on the initial post-infarction imaging, or to hemorrhagic infarction that can be confirmed from the first scan. By treatment context, HT can be classified as spontaneous or secondary (treatment-related); by clinical impact, it can be classified as symptomatic intracerebral hemorrhage (sICH) or asymptomatic intracerebral hemorrhage (aICH) [4].

Although reperfusion techniques continue to improve, HT remains a frequent clinical event — and symptomatic HT carries an extremely poor prognosis. IST-3 data show that, among patients with sICH, only 8% achieve functional independence at 6 months [5].On imaging, ECASS criteria distinguish hemorrhagic infarction (HI) from parenchymal hematoma (PH) [4]. ECASS I/II indicated that PH2-type hemorrhage is closely associated with early neurologic deterioration and 3-month mortality; in ECASS II, mortality among PH2 patients approached 50% [4].

A secondary analysis of ENCHANTED enrolled 4,370 AIS patients receiving IVT: 17.8% developed intracranial hemorrhage (sICH 1.4%, aICH 16.4%), and aICH remained significantly associated with poor outcomes [6]. A meta-analysis of 10 studies covering 5,723 EVT patients found aICH after EVT significantly associated with worse 90-day functional outcome (OR=2.17) and higher mortality (OR=1.72) [7]. A multicenter retrospective study of 3,067 patients across 10 stroke centers likewise confirmed that aICH was independently associated with poor 3-month outcomes and higher mortality [8].

Prof. Zhang emphasized that once HT occurs — regardless of whether clinical symptoms worsen — it constitutes an adverse clinical event that cannot be ignored. Pursuing recanalization must be accompanied by attention to cerebral cytoprotection, which remains a weak link in current clinical practice.

Risk Factors for Hemorrhagic Transformation: Multidimensional and Interwoven

HT does not arise from any single factor but from the interplay of multiple risks [9-11]. Clinical practice requires a multidimensional integrated assessment system, rather than relying on any single indicator for risk prediction.

Among treatment-related factors, IVT is a recognized HT trigger. Prof. Zhang noted that the IRIS study showed IVT increased bleeding risk, though the increase was primarily in asymptomatic hemorrhage, without a significant rise in symptomatic bleeding [12]. Vascular recanalization itself, and periprocedural medications such as heparin anticoagulation, may also be risk factors.

Stroke severity (baseline NIHSS) and baseline infarct core size are the most widely accepted risk factors closely tied to HT [9-11].

On clinical metrics, Prof. Zhang detailed the critical roles of blood pressure, glucose, and coagulation:First, blood pressure variability. Clinical studies show that BP variability within the first 24 hours after AIS admission correlates with poor prognosis and early death [13,14].

Second, stress hyperglycemia. Stress-induced glucose elevation after stroke is an important HT risk factor. Studies show that, regardless of diabetes history, a high stress hyperglycemia ratio (SHR) is an independent HT risk factor [15]. A study of 485 EVT patients showed that each 10 mg/dL rise in glucose significantly increased the risk of more severe ICH (cOR=1.06, 95% CI 1.03-1.09, P<0.001), with parallel increases in 90-day poor outcomes [16]. According to the 2026 AHA/ASA Guideline for the Early Management of Patients With Acute Ischemic Stroke [17], the appropriate range of glucose management warrants further investigation — both hypoglycemia and hyperglycemia carry risk.

On laboratory indicators, fibrinogen is an important HT predictor. A multicenter study of 1,678 patients showed that fibrinogen depletion (defined as fibrinogen <200 mg/dL at 2 hours post-thrombolysis or a ≥50% decrease from baseline) increased sICH risk by 55% (OR=1.55, 95% CI 1.04-2.32); 31% of sICH cases could be attributed to fibrinogen depletion, and depleted patients had lower rates of good 3-month functional recovery (61.5% vs 67.9%, P=0.012) [18].

On imaging predictors, leukoaraiosis and diffusion-weighted imaging (DWI) abnormal volume are both valuable. A meta-analysis found sICH in 9% of patients with severe leukoaraiosis versus 4% in those without [19]. DWI abnormal volume is also an important sICH predictor — the larger the volume, the higher the HT risk; with volumes ≥25 cm³, predictive sensitivity exceeds 90% [20].

BBB Disruption and Cerebral Cytoprotection: Targeting the Root Cause.The clinical dilemma of HT originates in post-stroke structural and functional disruption of the neurovascular unit and BBB, ultimately leading to hemorrhage [2,3].

A core goal of cerebral cytoprotection is precisely to protect the BBB and maintain functional homeostasis of the neurovascular unit; reperfusion combined with cerebral cytoprotection is therefore a potential strategy for reducing HT [21]. This strategy has been validated by the TASTE series of studies. The TASTE-2 trial showed that adjunctive use of edaravone dexborneol during endovascular thrombectomy significantly increased the proportion of patients achieving 90-day functional independence, with the benefit particularly pronounced in patients with an ischemic penumbra [22]. Edaravone dexborneol protects brain cells through multiple targets, combining free radical scavenging with anti-inflammatory action [23]; by protecting BBB integrity and mitigating reperfusion injury throughout the pre-, intra-, and post-reperfusion stages, it reduces HT risk and more fully translates the gains of recanalization into patients’ functional independence [22,24,25].

Summary

In AIS management, recanalization and cerebral cytoprotection are not interchangeable; both are essential. The former addresses restoration of blood flow; the latter addresses maintenance of neurovascular unit homeostasis. Reperfusion therapy gives patients the opportunity for timely blood flow restoration, but without effective cerebral cytoprotection, the HT caused by BBB disruption will substantially erode the gains of recanalization. Reducing HT risk depends not only on advances in reperfusion technique, but also on active intervention across multiple pathologic steps of the ischemic cascade.

References

[1] Chinese Medical Association Neurology Branch, Cerebrovascular Disease Group. Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023 [J]. Chin J Neurol, 2024, 57(6):523-559.

[2] Guo P, Li H, Zhang X, et al. Matrix metalloproteinase-9 in hemorrhagic transformation after acute ischemic stroke (Review) [J]. Mol Med Rep, 2025, 32(2).

[3] Lakhan S E, Kirchgessner A, Tepper D, et al. Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke [J]. Front Neurol, 2013, 4:32.

[4] Chinese Medical Association Neurology Branch, Cerebrovascular Disease Group. Chinese Expert Consensus on Diagnosis and Treatment of Hemorrhagic Transformation after Acute Ischemic Stroke 2019 [J]. Chin J Neurol, 2019, 52(4):252-265.

[5] Whiteley W N, Thompson D, Murray G, et al. Targeting rtPA in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the IST-3 trial [J]. Stroke, 2014, 45(4):1000.

[6] Wang Y, Maeda T, You S, et al. Patterns and Clinical Implications of Hemorrhagic Transformation After Thrombolysis in Acute Ischemic Stroke: Results From the ENCHANTED Study [J]. Neurology, 2024, 103(11):e210020.

[7] Harker P, Aziz Y N, Vranic J, et al. Asymptomatic Intracerebral Hemorrhage Following Endovascular Stroke Therapy Is Not Benign: A Systematic Review and Meta-Analysis [J]. J Am Heart Assoc, 2024, 13(4):e031749.

[8] Guasch-Jiménez M, Ezcurra Díaz G, Lambea-Gil Á, et al. Influence of Asymptomatic Hemorrhagic Transformation After Endovascular Treatment on Stroke Outcome: A Population-Based Study [J]. Neurology, 2025, 104(9):e213509.

[9] Neacă I, Negroiu C E, Tudorașcu I, et al. Risk Factors and Outcomes of Hemorrhagic Transformation in Acute Ischemic Stroke Following Thrombolysis: Analysis of a Single-Center Experience and Review of the Literature [J]. Medicina (Kaunas), 2025, 61(4).

[10] Bagoly Z. Hemorrhagic transformation after acute ischemic stroke thrombolysis treatment: navigating the landscape of hemostasis genetic risk factors [J]. J Thromb Haemost, 2024, 22(4):919-921.

[11] Yang J, Zhou J H. Research progress on blood biochemical and imaging predictors of hemorrhagic transformation in acute ischemic stroke [J]. Med Inf, 2024, 37(12):183-188.

[12] Majoie C B, Cavalcante F, Gralla J, et al. Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke: individual participant data meta-analysis of six randomised trials [J]. Lancet, 2023, 402(10406):965-974.

[13] Stead L G, Enduri S, Bellolio M F, et al. The impact of blood pressure hemodynamics in acute ischemic stroke: a prospective cohort study [J]. Int J Emerg Med, 2012, 5(1):3.

[14] Kellert L, Hametner C, Ahmed N, et al. Reciprocal Interaction of 24-Hour Blood Pressure Variability and Systolic Blood Pressure on Outcome in Stroke Thrombolysis [J]. Stroke, 2017, 48(7):1827-1834.

[15] Liu S, Gao J, Zhao H, et al. Impact of blood pressure variability on hemorrhagic transformation post-rt-PA thrombolysis in patients with acute ischemic stroke [J]. SAGE Open Med, 2024, 12:20503121241283881.

[16] Aziz Y N, Vagal V, Mehta T V, et al. Higher blood glucose is associated with the severity of hemorrhagic transformation after endovascular therapy for stroke [J]. J Stroke Cerebrovasc Dis, 2024, 33(8):107823.

[17] Prabhakaran S, Gonzalez N R, Zachrison K S, et al. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association [J]. Stroke, 2026.

[18] Romoli M, Vandelli L, Bigliardi G, et al. Fibrinogen Depletion Coagulopathy Predicts Major Bleeding After Thrombolysis for Ischemic Stroke: A Multicenter Study [J]. Stroke, 2022, 53(12):3671-3678.

[19] Charidimou A, Pasi M, Fiorelli M, et al. Leukoaraiosis, Cerebral Hemorrhage, and Outcome After Intravenous Thrombolysis for Acute Ischemic Stroke: A Meta-Analysis (v1) [J]. Stroke, 2016, 47(9):2364-2372.

[20] Caparros F, Kuchcinski G, Drelon A, et al. Use of MRI to predict symptomatic haemorrhagic transformation after thrombolysis for cerebral ischaemia [J]. J Neurol Neurosurg Psychiatry, 2020, 91(4):402-410.

[21] Chinese Geriatric Medical Association Cerebrovascular Disease Branch, Xia J, Zhu Y C. Chinese Expert Consensus on Clinical Practice of Cerebral Cytoprotection in Ischemic Stroke [J]. Int J Neurol Neurosurg, 2025, 52(2):1-7.

[22] Wang C, Gu H, Huo X, et al. Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial [J]. BMJ, 2026, 392:e086850.

[23] Chen H S, Zhao Z A, Shen X Y, et al. Edaravone dexborneol for ischemic stroke with sufficient recanalization after thrombectomy: a randomized phase II trial [J]. Nat Commun, 2025, 16(1):2393.

[24] Xu J, Wang A, Meng X, et al. Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial [J]. Stroke, 2021, 52(3):772-780.

[25] Fu Y, Wang A, Tang R, et al. Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial [J]. JAMA Neurol, 2024, 81(4):319-326.

0
0
Loading